Outlook Therapeutics
OTLK
Outlook Therapeutics (OTLK) earnings history
Most recent quarter
- Fiscal period
- Q3 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.14
- EPS estimate
- −$0.08
- EPS surprise
- −75.00%
- Revenue surprise
- −99.07%
- Revenue
- $9,000.00
- Revenue estimate
- $966,667.00
- Reported
- Aug 14, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2026 | Aug 14, 2026 | −$0.08 | −$0.14 | −75.00% | $9,000.00 | SEC |
| Q4 2025 | Dec 19, 2025 | −$0.26 | −$0.06 | +76.92% | −$100,000.00 | SEC |
| Q3 2025 | Aug 14, 2025 | −$0.35 | −$0.44 | −24.82% | $1.5M | SEC |
| Q2 2025 | May 15, 2025 | −$0.54 | −$0.40 | +26.31% | $0.00 | SEC |
| Q1 2025 | Feb 14, 2025 | −$0.76 | −$0.89 | −17.11% | $0.00 | SEC |
| Q4 2024 | Dec 27, 2024 | −$0.80 | −$0.88 | −9.55% | $0.00 | SEC |
| Q3 2024 | Aug 14, 2024 | −$1.03 | −$0.83 | +19.64% | $0.00 | SEC |
| Q2 2024 | May 15, 2024 | −$0.91 | −$1.55 | −70.35% | $0.00 | SEC |
| Q1 2024 | Feb 14, 2024 | −$0.99 | −$0.80 | +19.57% | $0.00 | SEC |
| Q4 2023 | Dec 22, 2023 | −$1.15 | −$1.00 | +13.04% | $0.00 | SEC |
| Q3 2023 | Aug 14, 2023 | −$1.05 | −$1.60 | −52.38% | $0.00 | SEC |
| Q2 2023 | May 15, 2023 | −$1.28 | −$0.60 | +53.18% | $0.00 | SEC |
| Q1 2023 | Feb 14, 2023 | −$1.19 | −$1.60 | −34.45% | $0.00 | SEC |
| Q4 2022 | Dec 29, 2022 | −$1.33 | −$1.20 | +9.58% | $0.00 | — |
| Q3 2022 | Aug 10, 2022 | −$1.47 | −$1.60 | −9.09% | $0.00 | — |
| Q2 2022 | May 13, 2022 | −$1.20 | −$1.80 | −50.00% | $0.00 | — |
| Q1 2022 | Feb 14, 2022 | −$1.20 | −$1.60 | −33.33% | $0.00 | — |
| Q4 2021 | Dec 22, 2021 | −$1.27 | −$1.60 | −26.31% | $0.00 | — |
| Q3 2021 | Aug 13, 2021 | −$1.40 | −$1.40 | +0.00% | $0.00 | — |
| Q2 2021 | May 14, 2021 | −$1.93 | −$1.80 | +6.89% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Outlook Therapeutics (OTLK) last report earnings?
Outlook Therapeutics last reported on Aug 14, 2026, covering fiscal Q3 2026.
Did OTLK beat earnings estimates?
No. Outlook Therapeutics reported EPS of −$0.14 for Q3 2026 against a −$0.08 estimate — a 75.00% miss.
How much revenue did OTLK report last quarter?
Outlook Therapeutics reported $9,000.00 in revenue for Q3 2026, against a consensus estimate of $966,667.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.